Collegium Pharmaceutical Completes Acquisition and Names New Director

Canton, Massachusetts, May 12 2026. Collegium Pharmaceutical Inc. completed an acquisition of assets and elected a new director, according to an 8-K filed with the SEC on the same day.

The filing discloses Item 2.01 Completion of Acquisition or Disposition of Assets, Item 5.02 Departure or Election of Directors or Principal Officers, Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. Collegium Pharmaceutical Inc., ticker COLL and CIK 0001267565, is a public company whose shares trade on Nasdaq.

Item 2.01 requires the company to name the parties to the transaction, the form and amount of consideration transferred and the exact closing date. Item 5.02 identifies the individual elected to the board, the effective date of the appointment and whether any specific cause or committee assignment is cited.

Because the filing is the primary record, exact dollar figures, stock or cash components and the identity of the acquired assets or target entity must be taken from the exhibits or body text incorporated by reference.

The operational change replaces the prior board composition with the addition of the named director effective May 12 2026 or the closing date stated in Item 2.01. The acquisition shifts ownership of the identified assets to Collegium, altering its balance sheet from the prior state.

Standard SEC rules require the company to file any required audited historical financial statements of the acquired business and pro forma financial information within 71 days of the initial 8-K if not furnished today.

Downstream, the completed acquisition starts the clock for any post-closing contractual milestones such as earn-out measurements or integration steps outlined in the purchase agreement. The new director assumes fiduciary duties immediately and may be assigned to existing committees, requiring updated committee charters or board resolutions.

Collegium must also ensure the Regulation FD disclosure in Item 7.01 does not selectively reveal material nonpublic information, or it must simultaneously disseminate that information to the public. Markets and data providers will incorporate the new director and the acquisition accounting into governance and financial models once the full exhibits become available.

This 8-K represents the official closing notice for the transaction first announced in an earlier filing. Public companies must report material acquisitions and board changes on Form 8-K within four business days under Items 2.01 and 5.02. The exhibits attached to the May 12 filing contain the press release and any material agreements required to be filed under Item 9.01.